Activity
Mon
Wed
Fri
Sun
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
What is this?
Less
More

Memberships

World Peptide Resource Hub

101 members • $7/month

2 contributions to World Peptide Resource Hub
🧬 RETATRUTIDE UPDATE: Phase 3 Data Just Dropped — And It Confirms What Many of Us Biohackers Already Knew
For those of us who’ve already been experimenting with retatrutide through research-grade sources, Eli Lilly’s new Phase 3 data is basically official validation. The mainstream is finally catching up to what early adopters have been experiencing in real time: this compound is on a completely different level from the standard GLP-1/GIP agonists. 📊 The Phase 3 Numbers Are Wild (But Honestly… Not Surprising) The TRIUMPH-4 late-stage clinical trial showed: - ~28.7% average weight reduction over 68 weeks - Over 70 lbs lost on average at the highest dose - Almost 40% of participants dropped 30%+ of their total body weight - Significant improvements in knee osteoarthritis pain and functional mobility For anyone who's used retatrutide consistently, this lines up with lived experience:more aggressive fat loss, faster, and with a metabolic “drive state” you don’t get from GLP-1s alone. 🔬 Why It Outperforms GLP-1s Retatrutide is a triple agonist — GLP-1 + GIP + glucagon.This multi-pathway activation is what biohackers have been calling the “holy trinity” of metabolic modulation: - GLP-1 = appetite suppression + slower gastric emptying - GIP = enhanced insulin response + energy partitioning - Glucagon = increased fat oxidation + metabolic acceleration When all three are firing, you get that stacked effect that feels very different from semaglutide or tirzepatide. ⚠️ Side Effects & Tolerability (From Both Trial and Real-World Use) Lilly’s data highlights the same things many of us have seen firsthand: - Nausea, diarrhea, and early-cycle GI turbulence - A subset of users tapping out due to side effects - Some stopping because the weight loss was “too much, too fast” Nothing shocking — but definitely a reminder that dose ramping is everything with this compound. 📅 What’s Coming Next More Phase 3 readouts will continue through 2026, but if these results hold, retatrutide is going to completely reshape the metabolic-therapeutics landscape.
2 likes • 3d
I started in September, low dosage. Down 35lbs..
1 like • 3d
Thank you!
🚨 31 Free-for-Life Spots Left (Then It’s $7/mo)
Quick update for everyone already inside 👇 This Skool community is brand new, and the first 100 members are FREE for life. We’re currently at 69 members, which means YOU are locked in for life at $0/mo 🙌 After we hit 100, new members will need to invest $7/month to access this education + resources. That also means we have 31 free-for-life spots left. If you know a friend who would benefit from peptides/biohacking education, please share this invite link so they can grab a free-for-life spot before it’s gone: https://www.skool.com/world-peptide-resource-hub-2344/about?ref=c5b4d6b59fe44e67b27ed0bd2e474ce3 Let’s build this the right way—smart, informed, and community-driven 🔥
2 likes • 3d
Awesome!
1-2 of 2
Derrick Duruseau
1
3points to level up
@derrick-duruseau-3861
Looking for a better health journey! Pushing myself to a new limit!

Active 14h ago
Joined Dec 14, 2025